📈 Pfizer's Earnings Are a Shot in the Arm

Together With

Advertise with us | Our Newsletters | Your Rewards

Good Morning!

The US job market might be in a bit of a slump, with job openings on the decline and layoffs at a two-year high. Pfizer also released its first-quarter earnings report and not only did they manage to meet Wall Street's expectations, they actually exceeded them - even with slipping sales.

Growth stocks have been dominating the market lately, but we've got our eyes on some hidden gems in the cybersecurity and data services sectors that are just waiting to be discovered.

Let’s dive in 👇️ 

Invest in The Company Potentially Pioneering Robotics in Surgery (Sponsor)
Did you know 100,000 knee replacements fail every single year? Enter Monogram, the brainchild of Dr. Doug Unis and Benjamin Sexson. They've set their sights on transforming the knee replacement industry by working to kick those out-dated methods to the curb.

With a $19.4B market Monogram is developing innovative surgical robots that will utilize cement-free, 3D-printed implants and advanced robotic precision that hope to put an end to post surgery joint pain and instability. Backed by $38M in funding, 20 patent applications, and on the path towards FDA approval, Monogram believes they are positioned ahead of the competition.

Now's your chance to invest in the potential future of knee surgery! Support Monogram's pursuit of happier, pain-free knees, and give your investment portfolio a potential boost it deserves*.

Invest before Monogram’s planned Nasdaq listing. The last day to fund your investment is on 5/10.

Markets

Dow tumbles more than 300 points as banking sector worries reignite before Fed rate decision (2 minute read)
Traders are feeling jittery about the possibility of more financial institutions getting infected with the same regional banking sector bug that's been going around. The Dow Jones Industrial Average plunged over 367 points, while the S&P 500 and Nasdaq Composite followed suit with their own declines. Even bank shares weren't safe, with the SPDR S&P Regional Banking ETF dropping over 6%. Things got especially scary for regional banks like PacWest and Western Alliance, which took a 27% and 15% hit, respectively.

US job openings drop; layoffs hit highest level in more than two years (3 minute read)
It looks like the US job market might be losing a little steam, with job openings dropping for the third straight month in March and layoffs hitting a two-year high. But don't panic just yet! The Federal Reserve might be able to use this slowdown to fight inflation. According to the monthly Job Openings and Labor Turnover Survey (JOLTS), there were still 1.6 vacancies for every unemployed person in March, so the market is still pretty tight. The Fed is keeping a close eye on this ratio as they wrap up their two-day policy meeting.

Investing

The Case for Buying Bitcoin as Debt Ceiling Absurdity Reemerges? (5 minute read)
Yesterday, Treasury Secretary Janet Yellen sent Congress a letter that basically said, "Hey, if you don't pass legislation to raise the debt ceiling, we might default on our debt by June 1st." Yikes! But before you go hoarding canned goods and ammo, remember that the U.S. has never actually defaulted on its debt before. Phew! If you're still feeling a little nervous, you could always consider some "anti-dollar" options like Bitcoin. Sure, it's a little wacky to some, but holding some BTC could offer a small measure of protection against the chaos that might ensue if Congress doesn't get its act together. After all, who doesn't like an asset that's based on the belief that politicians can't be trusted with our money?

Pfizer earnings and revenue top expectations despite Covid vaccine sales decline (4 minute read)
Hold on to your lab coats, folks! Pfizer (PFE) just announced its earnings for the first quarter, and even though the demand for its Covid vaccine has slowed down, the company still managed to exceed Wall Street's expectations. Sure, sales were down by 29% from last year, but with revenues of $18.28 billion, we're not exactly talking small potatoes here. Plus, Pfizer is keeping its chin up by maintaining its 2023 sales forecast of $67 billion to $71 billion. Looks like things are still looking pretty healthy over in the world of Big Pharma!

2 Growth Stocks to Buy in May (5 minute read)
Growth stocks have been on a roll lately, but some hidden gems are still waiting to be discovered. Take cybersecurity and data services, for instance - these areas are ripe for investment, with major players in these fields poised to bring in some serious wins. With the number of cyber threats continuing to rise, CrowdStrike's (CRWD) AI-powered platform is ahead of the game, constantly improving to stay on top of new dangers. Meanwhile, Snowflake's (SNOW) platform-agnostic data warehousing software is making waves by making it easy to analyze data from multiple cloud infrastructure providers.

🐥

Best of Twitter

Thanks for reading, if you enjoyed, tell your friends!

P.S: If you're interested in crypto and web3 - check out our new newsletter, The Crypto Journal!

Share The Investing Journal with your friends to receive rewards!

*Disclosure: This is a paid advertisement for Monogram Orthopedics’ Regulation A+ offering. Learn more at invest.monogramorthopedics.com/disclaimers